Trials / Completed
CompletedNCT04265209
[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- 35 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Clinical study to demonstrate an at least equivalent performance of a new PET molecular Imaging radiopharmaceutical named \[18F\] LBT-999 in brain imaging compared to the SPECT reference method named \[123I\]-FP-CIT to establish the differential diagnosis between Parkinson's Disease and Essential Tremor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPECT | \[123I\]-FP-CIT SPECT imaging procedure |
| DRUG | PET | \[18F\] LBT-999 PET imaging procedure |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2024-08-02
- Completion
- 2024-08-02
- First posted
- 2020-02-11
- Last updated
- 2025-11-17
Locations
16 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04265209. Inclusion in this directory is not an endorsement.